Hurley Capital’s Roivant Sciences ROIV Stock Holding History

Hurley Capital’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.29K	Hold	206	–	–	﹤0.01%	359
2026 Q1	$5.71K	Buy	+206	New	+$5.29K	﹤0.01%	405
2025 Q4	–	Sell	-413	Closed	-$6.25K	–	728
2025 Q3	$6.25K	Buy	+413	New	+$5.11K	﹤0.01%	412

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Hurley Capital's ROIV Position: Q2 2026 in Review

Hurley Capital held its Roivant Sciences (ROIV) position steady in Q2 2026 at 206 shares worth $7.29K. The position accounts for ﹤0.01% of the portfolio, ranked #359.

Hurley Capital first reported a position in ROIV in Q3 2025 and has held it in 3 quarters since. 500 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

Hurley Capital held 206 shares of Roivant Sciences worth $7.29K as of Q2 2026.
Hurley Capital left its Roivant Sciences share count unchanged in Q2 2026.
Roivant Sciences made up ﹤0.01% of Hurley Capital's portfolio in Q2 2026, its #359 holding.
Hurley Capital first reported a position in Roivant Sciences in Q3 2025 and has held it in 3 quarters since.
500 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Hurley Capital's 13F filing for Q2 2026, filed 10 Aug 2026.